scholarly journals AttenuatedBordetella pertussisBPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route

2011 ◽  
Vol 2 (6) ◽  
pp. 315-319 ◽  
Author(s):  
Rui Li ◽  
Annabelle Lim ◽  
Sylvie Alonso
Keyword(s):  
Nasal Route ◽  
Vaccine Antigens

Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens

Vaccine ◽  
2001 ◽  
Vol 19 (30) ◽  
pp. 4236-4244 ◽  
Author(s):  
C Klinguer ◽  
A Beck ◽  
P De-Lys ◽  
M.C Bussat ◽  
A Blaecke ◽  
...  
Keyword(s):  
Ammonium Salt ◽  
Quaternary Ammonium ◽  
Quaternary Ammonium Salt ◽  
Mucosal Adjuvant ◽  
Nasal Route ◽  
Vaccine Antigens

Seeds as Economical Production Platform for Recombinant Proteins

2020 ◽  
Vol 27 (2) ◽  
pp. 89-104 ◽  
Author(s):  
Muhammad Sarwar Khan ◽  
Faiz Ahmad Joyia ◽  
Ghulam Mustafa
Keyword(s):  
Oral Delivery ◽  
High Protein ◽  
Biologically Active ◽  
Cold Chain ◽  
Protein Accumulation ◽  
Long Term Storage ◽  
Production Platform ◽  
Vaccine Antigens ◽  
Term Storage

: The cost-effective production of high-quality and biologically active recombinant molecules especially proteins is extremely desirable. Seed-based recombinant protein production platforms are considered as superior choice owing to lack of human/animal pathogenic organisms, lack of cold chain requirements for transportation and long-term storage, easy scalability and development of edible biopharmaceuticals in plants with objective to be used in purified or partially processed form is desirable. This review article summarizes the exceptional features of seed-based biopharming and highlights the needs of exploiting it for commercial purposes. Plant seeds offer a perfect production platform for high-value molecules of industrial as well as therapeutic nature owing to lower water contents, high protein storage capacity, weak protease activity and long-term storage ability at ambient temperature. Exploiting extraordinarily high protein accumulation potential, vaccine antigens, antibodies and other therapeutic proteins can be stored without effecting their stability and functionality up to years in seeds. Moreover, ability of direct oral consumption and post-harvest stabilizing effect of seeds offer unique feature of oral delivery of pharmaceutical proteins and vaccine antigens for immunization and disease treatment through mucosal as well as oral route.

scholarly journals The identification of novel immunogenic antigens as potential Shigella vaccine components

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Ruklanthi de Alwis ◽  
Li Liang ◽  
Omid Taghavian ◽  
Emma Werner ◽  
Hao Chung The ◽  
...  
Keyword(s):  
Core Genome ◽  
Genomic Analysis ◽  
Carrier Proteins ◽  
Vaccine Candidates ◽  
Vaccine Antigens ◽  
Bactericidal Antibody ◽  
In Vivo Testing ◽  
Species Specific ◽  
Selection Of

Abstract Background Shigella is a major diarrheal pathogen for which there is presently no vaccine. Whole genome sequencing provides the ability to predict and derive novel antigens for use as vaccines. Here, we aimed to identify novel immunogenic Shigella antigens that could serve as Shigella vaccine candidates, either alone, or when conjugated to Shigella O-antigen. Methods Using a reverse vaccinology approach, where genomic analysis informed the Shigella immunome via an antigen microarray, we aimed to identify novel immunogenic Shigella antigens. A core genome analysis of Shigella species, pathogenic and non-pathogenic Escherichia coli, led to the selection of 234 predicted immunogenic Shigella antigens. These antigens were expressed and probed with acute and convalescent serum from microbiologically confirmed Shigella infections. Results Several Shigella antigens displayed IgG and IgA seroconversion, with no difference in sero-reactivity across by sex or age. IgG sero-reactivity to key Shigella antigens was observed at birth, indicating transplacental antibody transfer. Six antigens (FepA, EmrK, FhuA, MdtA, NlpB, and CjrA) were identified in in vivo testing as capable of producing binding IgG and complement-mediated bactericidal antibody. Conclusions These findings provide six novel immunogenic Shigella proteins that could serve as candidate vaccine antigens, species-specific carrier proteins, or targeted adjuvants.

scholarly journals Identification of linear epitopes on the flagellar proteins of Clostridioides difficile

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
A. Razim ◽  
K. Pacyga ◽  
P. Naporowski ◽  
D. Martynowski ◽  
A. Szuba ◽  
...  
Keyword(s):  
Digestive Tract ◽  
In Silico ◽  
Anaerobic Bacterium ◽  
Vaccine Antigen ◽  
Protective Properties ◽  
Clostridioides Difficile ◽  
Vaccine Antigens ◽  
Linear Epitopes ◽  
Flagellar Proteins

AbstractClostridioides difficile (C. difficile) is an opportunistic anaerobic bacterium that causes severe diseases of the digestive tract of humans and animals. One of the possible methods of preventing C. difficile infection is to develop a vaccine. The most promising candidates for vaccine antigens are the proteins involved in the adhesion phenomena. Among them, the FliC and FliD are considered to be suitable candidates. In this paper, the FliC and FliD protein polypeptide epitopes were mapped in silico and by using PEPSCAN procedure. We identified four promising epitopes: 117QRMRTLS123, 205MSKAG209 of FliC and 226NKVAS230, 306TTKKPKD312 of FliD protein. We showed that 117QRMRTLS123 sequence is not only located in TLR5-binding and activating region, as previously shown, but forms an epitope recognized by C. difficile-infected patients’ antibodies. 205MSKAG209 is a C. difficile-unique, immunogenic sequence that forms an exposed epitope on the polymerized flagella structure which makes it a suitable vaccine antigen. 226NKVAS230 and 306TTKKPKD312 are well exposed and possess potential protective properties according to VaxiJen analysis. Our results open the possibility to use these epitopes as suitable anti-C. difficile vaccine antigens.

Olfactory mucosa stem cells delivery via nasal route: a simple way for the treatment of Parkinson disease

2021 ◽  
Author(s):  
Sara Simorgh ◽  
Rafieh Alizadeh ◽  
Ronk Shabani ◽  
Fariba Karimzadeh ◽  
Elham Seidkhani ◽  
...  
Keyword(s):  
Stem Cells ◽  
Parkinson Disease ◽  
Olfactory Mucosa ◽  
Nasal Route

scholarly journals Continuous HIV-1 Escape from Autologous Neutralization and Development of Cross-Reactive Antibody Responses Characterizes Slow Disease Progression of Children

Vaccines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 260
Author(s):  
Stefania Dispinseri ◽  
Mariangela Cavarelli ◽  
Monica Tolazzi ◽  
Anna Maria Plebani ◽  
Marianne Jansson ◽  
...  
Keyword(s):  
Disease Progression ◽  
Antibody Responses ◽  
Viral Escape ◽  
Target Cells ◽  
Transmitted Virus ◽  
Slow Progressors ◽  
Vaccine Antigens ◽  
Kinetics Of ◽  
Hiv 1

The antibodies with different effector functions evoked by Human Immunodeficiency Virus type 1 (HIV-1) transmitted from mother to child, and their role in the pathogenesis of infected children remain unresolved. So, too, the kinetics and breadth of these responses remain to be clearly defined, compared to those developing in adults. Here, we studied the kinetics of the autologous and heterologous neutralizing antibody (Nab) responses, in addition to antibody-dependent cellular cytotoxicity (ADCC), in HIV-1 infected children with different disease progression rates followed from close after birth and five years on. Autologous and heterologous neutralization were determined by Peripheral blood mononuclear cells (PBMC)- and TZMbl-based assays, and ADCC was assessed with the GranToxiLux assay. The reactivity to an immunodominant HIV-1 gp41 epitope, and childhood vaccine antigens, was assessed by ELISA. Newborns displayed antibodies directed towards the HIV-1 gp41 epitope. However, antibodies neutralizing the transmitted virus were undetectable. Nabs directed against the transmitted virus developed usually within 12 months of age in children with slow progression, but rarely in rapid progressors. Thereafter, autologous Nabs persisted throughout the follow-up of the slow progressors and induced a continuous emergence of escape variants. Heterologous cross-Nabs were detected within two years, but their subsequent increase in potency and breadth was mainly a trait of slow progressors. Analogously, titers of antibodies mediating ADCC to gp120 BaL pulsed target cells increased in slow progressors during follow-up. The kinetics of antibody responses to the immunodominant viral antigen and the vaccine antigens were sustained and independent of disease progression. Persistent autologous Nabs triggering viral escape and an increase in the breadth and potency of cross-Nabs are exclusive to HIV-1 infected slowly progressing children.

scholarly journals EVIDENCE OF ACTIVE IMMUNITY TO EXPERIMENTAL POLIOMYELITIS OBTAINED BY THE INTRANASAL ROUTE IN MACACUS RHESUS

1938 ◽  
Vol 67 (4) ◽  
pp. 529-544
Author(s):  
S. D. Kramer ◽  
L. H. Grossman ◽  
G. C. Parker
Keyword(s):  
Rhesus Monkey ◽  
Combined Treatment ◽  
Human Beings ◽  
Intranasal Route ◽  
Intranasal Infection ◽  
Nasal Route ◽  
Active Immunity ◽  
Intracerebral Infection ◽  
Usual Reaction

The experiments reported above indicate that the intranasal instillations of pituitrin S and adrephine, alter susceptibility in the rhesus monkey. One-half to two-thirds of the treated animals resisted intranasal infection, and, moreover, most of the resistant animals which had received combined treatment and virus developed active immunity, as indicated by the presence of neutralizing substance in their serums and by their ability to resist intracerebral infection. We have, it appears, not alone modified in some fashion the usual reaction of this animal to intranasal infection, but we have also successfully vaccinated these animals by the nasal route, so that the response in animals more nearly approaches what we believe to be the response in human beings. We have no knowledge of the mechanism by means of which pituitrin S and adrephine produce this apparent alteration in susceptibility, but since the outcome of continued exposure to virus in most of the animals treated with these substances results in immunity, we believe that this offers a more hopeful approach toward the control of the disease.

scholarly journals Bacillus anthracisEdema Toxin Acts as an Adjuvant for Mucosal Immune Responses to Nasally Administered Vaccine Antigens

2006 ◽  
Vol 176 (3) ◽  
pp. 1776-1783 ◽  
Author(s):  
Alexandra Duverger ◽  
Raymond J. Jackson ◽  
Frederick W. van Ginkel ◽  
Romy Fischer ◽  
Angela Tafaro ◽  
...  
Keyword(s):  
Immune Responses ◽  
Vaccine Antigens ◽  
Mucosal Immune Responses
Sign in / Sign up

Export Citation Format

Share Document